Idera squelch­es any lin­ger­ing en­thu­si­asm as its lead TLR9 drug flunks PhI­II — bad­ly

More than 3 years ago, with its stock rid­ing high, Idera $IDRA caused quite a stir at ES­MO with its TLR9 drug and the 44% ORR it tracked in a hand­ful of pa­tients suf­fer­ing from ad­vanced melanoma. The ORR for the Toll-like re­cep­tor 9 ag­o­nist dropped to 22% in Phase II. And on Thurs­day, the Phase III — its lead pro­gram — came out with a mis­er­able 8.8% ORR for its com­bo ap­proach us­ing ip­il­i­mum­ab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER